Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 DiabetesBusiness Wire • 03/27/23
The Cream Of The Crop: 5 Biotech Stocks That Outrank 91% Of All StocksInvestors Business Daily • 03/24/23
Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)Business Wire • 03/16/23
This HealthCare Company Is Gearing Up for Its Next Launch: Here Is Why The Stock Is a BuyThe Motley Fool • 03/10/23